Posts

Ketamine Study Suggests the Psychedelic Could Treat Parkinson's DiseaseShutterstock

Ketamine Study Suggests the Psychedelic Could Treat Parkinson’s Disease

PharmaTher evaluates safety, tolerability and efficacy of low-dose ketamine infusion for treatment of LID in Parkinson’s Disease patients.
Psychedelic Business Spotlight – December 17

Psychedelic Business Spotlight – December 17

,
This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Psychedelic Business Spotlight: December 3

,
This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

,
This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionShutterstock.com

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

,
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.

Psychedelic Business Spotlight: November 12

,
This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO...
Psychedelic Business Spotlight: November 5

Psychedelic Business Spotlight: November 5

,
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.

Psychedelic Business Spotlight: October 15

,
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
FDA Backs Ketamine for Rare Pain Disorder with No Current Medical Treatment

FDA Backs Ketamine to Treat This Rare and Debilitating Pain Syndrome

Food and Drug Administration grants psychedelic biotechnology company PharmaTher orphan drug designation for ketamine to treat complex regional pain syndrome.
Psychedelic Business Spotlight: October 8, 2021

Psychedelic Business Spotlight: October 8, 2021

,
This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat...